U.S. stock night market volatility: Biodexa Pharmaceuticals fell 4.32% in after-hours trading, with active trading causing fluctuations

U.S. Stock Night Market Movements Biodexa Pharmaceuticals fell 4.32% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry Recursion fell 1.68%. Based on recent key news: On December 9, Recursion Pharmaceuticals announced phase 1b/2 data for REC-4881, showing significant therapeutic effects, with the stock price rising about 3%. The drug demonstrated significant efficacy in trials for hereditary adenomatous polyposis, with a median reduction of 43% in participants' polyp burden, driving the stock price up. Source: Reuters On December 8, Recursion Pharmaceuticals' stock price rose 6.2% in pre-market trading to $5.05. The company stated that its experimental oral drug REC-4881 showed sustained therapeutic effects in early to mid-stage trials, with 9 patients maintaining a reduction in polyp burden 12 weeks after stopping the medication. Source: Reuters On December 8, Recursion Pharmaceuticals' AI platform achieved its first clinical validation, with the CEO stating that AI technology shows potential in drug discovery and safety testing, which could significantly shorten time and costs. This news has boosted market confidence in the company's technology. Source: Reuters. The application of AI technology in drug development is increasing. Moderna fell 0.55% in the night market. Based on recent news: On December 9, Moderna executive Klinger Shannon Thyme submitted Form 4, disclosing changes in stock ownership. This change includes the exercise of 47,190 stock options and the return of 22,817 shares to cover option exercise costs and tax liabilities. This news may trigger market attention on the company's insider trading, leading to stock price volatility. On December 10, U.S. health regulators are investigating death incidents related to the COVID-19 vaccine. Although Moderna reiterated that there are no new or undisclosed safety issues with its vaccine in children and pregnant women, this news may still raise market concerns about vaccine safety, affecting the stock price. On December 11, Moderna reached a collaboration agreement with Nanexa worth up to $500 million. The agreement includes development and commercial milestone payments as well as tiered royalties on future product sales. This collaboration may have a positive impact on Moderna's long-term development, but the market reaction in the short term has been mixed. The vaccine safety investigation has raised market concerns, while the collaboration agreement brings long-term benefits CRISPR Therapeutics fell 0.94% in after-hours trading. Based on recent news, On December 9, MarketBeat pointed out that CRISPR Therapeutics was not included in the list of five stocks recommended by top analysts, despite currently holding a "Hold" rating among analysts. This news may lead to a decline in investor confidence, affecting the stock price. On December 8, research found that the KaeCanABC system of Klebsiella aerogenes plays an important role in bacterial antiviral immunity and is highly homologous to human MALT1-like caspases. This discovery provides key insights into the cross-domain conservation of immune pathways but did not directly impact the stock price of CRISPR Therapeutics. On December 8, Simply Wall St published an article analyzing 3,577 penny stocks with strong financial conditions and 26 stocks reshaping industries using artificial intelligence, without mentioning CRISPR Therapeutics. This may lead some investors to turn to other recommended stocks. The gene editing industry has shown stable performance recently, with macroeconomic data remaining stable